Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
Why Iovance Stock Is Down 18% Today
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.
Iovance Biotherapeutics Reports a Q1 Revenue Miss
The biopharma upstart did match earnings expectations and continues to ramp up Amtagvi production.
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
Is this rising healthcare stock a good buy right now?
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies.
Is Iovance Biotherapeutics Stock a Buy Now?
Let's find out if this biotech can keep up its recent momentum.
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories.
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
This company's growth story is about to get moving with gusto.
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
Its revenue is set to grow, and one of its trials is no longer paused.
Valuation
Earnings Transcripts
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.